R
ROCKET PHARMACEUTICALS INC
NASDAQ: RCKT (Rocket Pharmaceuticals, Inc.)
Last update: 6 hours ago3.42
0.13 (3.95%)
| Previous Close | 3.29 |
| Open | 3.24 |
| Volume | 1,104,319 |
| Avg. Volume (3M) | 2,376,509 |
| Market Cap | 370,120,000 |
| Price / Book | 1.18 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.63 |
| Total Debt/Equity (MRQ) | 6.15% |
| Current Ratio (MRQ) | 9.19 |
| Operating Cash Flow (TTM) | -208.66 M |
| Levered Free Cash Flow (TTM) | -109.28 M |
| Return on Assets (TTM) | -34.80% |
| Return on Equity (TTM) | -60.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rocket Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.10 |
|
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.73% |
| % Held by Institutions | 93.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Monaco Asset Management Sam | 30 Sep 2025 | 2,892,261 |
| Newtyn Management, Llc | 30 Sep 2025 | 2,502,863 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 263.00 (JP Morgan, 7,590.06%) | Sell |
| Median | 9.50 (177.78%) | |
| Low | 7.00 (Leerink Partners, 104.68%) | Hold |
| Average | 72.25 (2,012.57%) | |
| Total | 2 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 3.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 18 Nov 2025 | 8.00 (133.92%) | Buy | 2.94 |
| JP Morgan | 18 Nov 2025 | 263.00 (7,590.06%) | Sell | 2.94 |
| Chardan Capital | 14 Oct 2025 | 11.00 (221.64%) | Buy | 4.27 |
| Leerink Partners | 03 Oct 2025 | 7.00 (104.68%) | Hold | 3.15 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MILITELLO JOHN | - | 2.94 | -1,086 | -3,193 |
| SCHWARTZ JONATHAN DAVID | - | 2.94 | -2,545 | -7,482 |
| SHAH GAURAV | - | 2.94 | -6,276 | -18,451 |
| WILSON MARTIN | - | 2.94 | -1,646 | -4,839 |
| Aggregate Net Quantity | -11,553 | |||
| Aggregate Net Value ($) | -33,966 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.94 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MILITELLO JOHN | Officer | 18 Nov 2025 | Sell (-) | 1,086 | 2.94 | 3,193 |
| SCHWARTZ JONATHAN DAVID | Officer | 18 Nov 2025 | Sell (-) | 2,545 | 2.94 | 7,482 |
| WILSON MARTIN | Officer | 18 Nov 2025 | Sell (-) | 1,646 | 2.94 | 4,839 |
| SHAH GAURAV | Officer | 18 Nov 2025 | Sell (-) | 6,276 | 2.94 | 18,451 |
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference |
| 06 Nov 2025 | Announcement | Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
| 14 Oct 2025 | Announcement | Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) |
| 10 Oct 2025 | Announcement | Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |